



Proactive.
Comprehensive.
Engaging.



Simplify heart failure management at home and reduce hospitalizations.¹

*for NYHA class III HF patients



CORDELLA® PULMONARY ARTERY (PA)
PRESSURE SENSOR & HEART FAILURE SYSTEM


Active Heart Failure Management At-Home.

Heart failure (HF) patients* spend most of their time outside the office. **Cordella keeps you connected.**

Cordella **supports remote medication adjustments for guideline-directed medical therapy (GDMT)**, providing trended PA pressure and vital sign data for informed care decisions.



As the **only remote HF management platform delivering comprehensive insights**, Cordella empowers proactive care to help prevent congestion, improve outcomes and potentially reduce unplanned office visits.

Cordella PA
Sensor Implant



At-home myCordella™
Patient Kit

Patient Prospective





Get Ahead. Decongest.

Proactively manage worsening HF from home to improve patient outcomes.

PA Pressure-Guided Therapy

An early and accurate indicator of congestion, PA pressure trends guide medical management to achieve target pressure and provide an indication of worsening HF.

Comprehensive Clinical Picture

Daily health metrics trended over time inform medication titration.

- Blood Pressure
- Weight
- Heart Rate
- Health Questions
- Blood Oxygen

Exceptional Patient Engagement

Promotes sustainable patient lifestyle changes with an easy-to-use platform that provides patient visibility to health data trends.

Streamlined Patient Care

Seamless clinic workflow integration with patient triaging and secure patient messaging simplifies remote patient management.

Simple Habits. Strong Engagement.

Patients need support to make sustainable lifestyle changes at home – **Cordella is here to help.**

The secure patient tablet provides timely and important feedback including visibility to daily health trends and communication with the care team.



95%

of patients want to see their health data⁴



97%

of Cordella patients believe PA pressure monitoring and resulting care has a positive health impact⁴




1 in 2

patients made lifestyle changes based on daily readings³




Clinically Proven to Enable Better HF Care.

In clinical trials for NYHA class III HF patients, **Cordella demonstrated a lower HFH/all-cause mortality event rate than historical PA pressure studies**, and significant improvement in key patient quality of life metrics.^{1,3,5}



Reduction in HF hospitalization (HFH) rate pre/post Cordella at 12 months¹

12-month Incidence of HF Hospitalizations or All-Cause Mortality



Kansas City Cardiomyopathy Questionnaire (KCCQ)

5.7-point clinical improvement¹

6-Minute Walk Test

35 m improvement¹

NT-proBNP

268 pg/mL decrease¹

Cordella has a proven safety profile with a low complication rate.^{1,3,5}

At 12-months the low incidence of serious adverse events included acute kidney injury (2.4%), bleeding (0.6%), myocardial infarction (0.4%), arrhythmia (10.1%), hemoptysis (3.0%).¹

Ordering Information

To place an order, send an email to orders@endotronix.com, call 888-512-5153, or speak with your Cordella sales representative.

Catalog No.	Description
CRDLA001US	Single Commercial System (1) Reader, (1) Delivery System, (1) Cordella System
CRDLA002US	Single Commercial Start Up Kit (1) Reader, (1) Delivery System, (1) Cordella System, (1) CalEq
CRDLA003US	Commercial Bundle (3) Readers, (3) Delivery Systems, (3) Cordella Systems
CRDLA004US	Commercial Start Up Bundle Kit (3) Readers, (3) Delivery Systems, (3) Cordella Systems, (1) CalEq

[Learn more about Cordella at endotronix.com](https://www.endotronix.com)

References

1. Klein L et al. Seated Pulmonary Artery Pressure Management in Patients with Heart Failure: 12-Month Outcomes in the PROACTIVE-HF Trial. Accepted in JACC-HF.
2. Data on file.
3. Sharif F et al. ESC Heart Fail. 2024Apr; 77(2):7733-7743.
4. Guichard JL et al. Presented at THT 2023, Boston MA.
5. Guichard JL et al. J Am Coll Cardiol HF. 2024 Aug 2:52273-7779(24)00485-2.

In the U.S., the Cordella™ PA Sensor System is Rx Only. CAUTION: Federal law restricts this device to sale by or on the order of a physician. In Europe, the Cordella™ PA Sensor System is Exclusively for Clinical Investigation.

See instructions for use for full prescribing information. As with any medical procedure, there is a possibility of risks. The most serious risks of the Cordella PA Sensor are similar to other heart procedures and include death, serious damage to the arteries, serious bleeding, breathing problems, renal (kidney issues), and worsening heart failure.

Edwards, Edwards Lifesciences, the stylized E logo, are trademarks of Edwards Lifesciences Corporation. Cordella and myCordella are trademarks of Endotronix, Inc. a wholly owned subsidiary of Edwards Lifesciences Corporation. The A&D marks are owned by A&D Engineering, Inc. and are used by Endotronix with permission of A&D Engineering, Inc.

All other trademarks are the property of their respective owners.

© 2025 Edwards Lifesciences Corporation. All rights reserved. ML6538 Rev B

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • [edwards.com](https://www.edwards.com)



Edwards